<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font16 { font-size : 16; } .font17 { font-size : 17; } .font18 { font-size : 18; } .font19 { font-size : 19; } .font20 { font-size : 20; } .font24 { font-size : 24; } .font10 { font-size : 10; } .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font30 { font-size : 30; } .font14 { font-size : 14; }</style>
 <body>
  <p>
   <span class="font30">migraine </span>
   <span class="font24">treatment </span>
   <span class="font20">patients </span>
   <span class="font20">chronic </span>
   <span class="font19">prophylactic </span>
   <span class="font18">CGRP </span>
   <span class="font17">headache </span>
   <span class="font16">Headache </span>
   <span class="font16">clinical </span>
   <span class="font14">antibodies </span>
   <span class="font14">migraine: </span>
   <span class="font14">{border-style </span>
   <span class="font13">./s--- </span>
   <span class="font13">monoclonal </span>
   <span class="font13">px;} </span>
   <span class="font13">receptor </span>
   <span class="font13">#ffffff;} </span>
   <span class="font13">study </span>
   <span class="font13">trial </span>
   <span class="font13">OBT-A </span>
   <span class="font13">prevention </span>
   <span class="font13">therapy </span>
   <span class="font13">Headache. </span>
   <span class="font13">Lipton </span>
   <span class="font13">[], </span>
   <span class="font13">episodic </span>
   <span class="font13">phase </span>
   <span class="font12">acute </span>
   <span class="font12">management </span>
   <span class="font12">./j.-...x </span>
   <span class="font12">Pain </span>
   <span class="font12">Pain. </span>
   <span class="font12">results </span>
   <span class="font12">review </span>
   <span class="font12">CM, </span>
   <span class="font12">received </span>
   <span class="font12">Chronic </span>
   <span class="font12">Italian </span>
   <span class="font12">Italy </span>
   <span class="font12">Neurol </span>
   <span class="font12">collab: </span>
   <span class="font12">currently </span>
   <span class="font12">effective </span>
   <span class="font12">peripheral </span>
   <span class="font12">reduce </span>
   <span class="font12">use </span>
   <span class="font12">Silberstein </span>
   <span class="font12">burden </span>
   <span class="font12">efficacy </span>
   <span class="font12">new </span>
   <span class="font12">patient </span>
   <span class="font12">topiramate </span>
   <span class="font12">trigeminal </span>
   <span class="font11">Dodick </span>
   <span class="font11">III </span>
   <span class="font11">Novartis, </span>
   <span class="font11">Teva </span>
   <span class="font11">advisory </span>
   <span class="font11">antagonists </span>
   <span class="font11">anti-CGRP </span>
   <span class="font11">central </span>
   <span class="font11">fees </span>
   <span class="font11">fremanezumab </span>
   <span class="font11">grants </span>
   <span class="font11">research </span>
   <span class="font11">risk </span>
   <span class="font11">treatments </span>
   <span class="font11">(e.g. </span>
   <span class="font11">Allergan, </span>
   <span class="font11">Bigal </span>
   <span class="font11">CM. </span>
   <span class="font11">Goadsby </span>
   <span class="font11">associated </span>
   <span class="font11">data </span>
   <span class="font11">need </span>
   <span class="font11">pain </span>
   <span class="font11">participation </span>
   <span class="font11">prevent </span>
   <span class="font11">px; </span>
   <span class="font11">{font-family </span>
   <span class="font11">Eli </span>
   <span class="font11">However, </span>
   <span class="font11">attacks </span>
   <span class="font11">boards, </span>
   <span class="font11">days </span>
   <span class="font11">diagnostic </span>
   <span class="font11">drugs </span>
   <span class="font11">evidence-based </span>
   <span class="font11">font-size </span>
   <span class="font11">frequency </span>
   <span class="font11">high-frequency </span>
   <span class="font11">placebo </span>
   <span class="font11">preventive </span>
   <span class="font11">progression </span>
   <span class="font11">release </span>
   <span class="font11">specifically </span>
   <span class="font11">versus </span>
   <span class="font11">Barbanti </span>
   <span class="font11">Cephalalgia. </span>
   <span class="font11">Curr </span>
   <span class="font11">Department </span>
   <span class="font11">Geppetti </span>
   <span class="font11">Migraine </span>
   <span class="font11">Patients </span>
   <span class="font11">Treatment </span>
   <span class="font11">best </span>
   <span class="font11">development </span>
   <span class="font11">double-blind, </span>
   <span class="font11">double; </span>
   <span class="font11">evidence </span>
   <span class="font11">help </span>
   <span class="font11">levels </span>
   <span class="font11">national </span>
   <span class="font11">nociceptive </span>
   <span class="font11">peptide </span>
   <span class="font11">potential </span>
   <span class="font11">strategy </span>
   <span class="font11">therapies </span>
   <span class="font11">tolerated </span>
   <span class="font11">used </span>
   <span class="font11">Anti-CGRP </span>
   <span class="font11">Buse </span>
   <span class="font11">International </span>
   <span class="font11">Martelletti </span>
   <span class="font11">OnabotulinumtoxinA </span>
   <span class="font11">PREEMPT </span>
   <span class="font11">Paolo </span>
   <span class="font11">Pini </span>
   <span class="font11">Rev </span>
   <span class="font11">Serrano </span>
   <span class="font11">Suppl </span>
   <span class="font11">Teva. </span>
   <span class="font11">Turkel </span>
   <span class="font11">University </span>
   <span class="font11">activation </span>
   <span class="font11">administered </span>
   <span class="font11">anti-CGRP/R </span>
   <span class="font11">appropriate </span>
   <span class="font11">attack </span>
   <span class="font11">available </span>
   <span class="font11">border-color </span>
   <span class="font11">border-width </span>
   <span class="font11">calcitonin </span>
   <span class="font11">care </span>
   <span class="font11">characteristics </span>
   <span class="font11">cortical </span>
   <span class="font11">current </span>
   <span class="font11">disability </span>
   <span class="font11">early </span>
   <span class="font11">economic </span>
   <span class="font11">gene-related </span>
   <span class="font11">grid..f </span>
   <span class="font11">healthcare </span>
   <span class="font11">high </span>
   <span class="font11">increased </span>
   <span class="font11">medications </span>
   <span class="font11">oral </span>
   <span class="font11">pathway </span>
   <span class="font11">pharmacological </span>
   <span class="font11">pilot </span>
   <span class="font11">placebo-controlled </span>
   <span class="font11">provide </span>
   <span class="font11">randomized, </span>
   <span class="font11">receive </span>
   <span class="font11">reducing </span>
   <span class="font11">role </span>
   <span class="font11">safety </span>
   <span class="font11">sensitisation </span>
   <span class="font11">solid; </span>
   <span class="font11">spreading </span>
   <span class="font11">support </span>
   <span class="font11">therapeutic </span>
   <span class="font11">trials </span>
   <span class="font11">using </span>
   <span class="font11">{font-style </span>
   <span class="font11">{font-weight </span>
   <span class="font10">(Fig. </span>
   <span class="font10">./head. </span>
   <span class="font10">Aurora </span>
   <span class="font10">Center, </span>
   <span class="font10">Grazzi </span>
   <span class="font10">Italy. </span>
   <span class="font10">Lilly, </span>
   <span class="font10">MOH </span>
   <span class="font10">Manack </span>
   <span class="font10">Maria </span>
   <span class="font10">Novartis </span>
   <span class="font10">Rapoport </span>
   <span class="font10">Rep </span>
   <span class="font10">Sarchielli </span>
   <span class="font10">Sciences, </span>
   <span class="font10">Springer </span>
   <span class="font10">TRP </span>
   <span class="font10">Topiramate </span>
   <span class="font10">action </span>
   <span class="font10">agents </span>
   <span class="font10">approach </span>
   <span class="font10">attacks, </span>
   <span class="font10">blood </span>
   <span class="font10">bold </span>
   <span class="font10">centers </span>
   <span class="font10">channels </span>
   <span class="font10">condition </span>
   <span class="font10">controlled </span>
   <span class="font10">cost </span>
   <span class="font10">courier; </span>
   <span class="font10">culture </span>
   <span class="font10">diagnosis </span>
   <span class="font10">different </span>
   <span class="font10">disease </span>
   <span class="font10">em; </span>
   <span class="font10">ensure </span>
   <span class="font10">factors, </span>
   <span class="font10">frequency, </span>
   <span class="font10">grid.. </span>
   <span class="font10">injection, </span>
   <span class="font10">medical </span>
   <span class="font10">medication </span>
   <span class="font10">migraine. </span>
   <span class="font10">multidisciplinary </span>
   <span class="font10">nervous </span>
   <span class="font10">occur </span>
   <span class="font10">onset </span>
   <span class="font10">options </span>
   <span class="font10">overuse </span>
   <span class="font10">pathophysiology </span>
   <span class="font10">procedures </span>
   <span class="font10">prophylaxis </span>
   <span class="font10">pt;} </span>
   <span class="font10">receptors </span>
   <span class="font10">reduced </span>
   <span class="font10">register </span>
   <span class="font10">relation </span>
   <span class="font10">severity </span>
   <span class="font10">social </span>
   <span class="font10">speaker </span>
   <span class="font10">specific </span>
   <span class="font10">strategies </span>
   <span class="font10">suggested </span>
   <span class="font10">symptoms </span>
   <span class="font10">tertiary </span>
   <span class="font10">toxin </span>
   <span class="font10">travel </span>
   <span class="font10">treatment, </span>
   <span class="font10">triptans </span>
   <span class="font10">writing </span>
  </p>
 </body>
</html>
